NCT05740501View on ClinicalTrials.gov

Pharmacokinetic Profiling of Pembrolizumab and Nivolumab in Patients With Melanoma and/or Non-Small Cell Lung Cancer

CompletedOBSERVATIONAL
Enrollment

13

Participants

Timeline

Start Date

April 26, 2017

Primary Completion Date

January 3, 2020

Study Completion Date

January 3, 2020

Conditions
Lung Non-Small Cell CarcinomaMelanoma
Interventions
PROCEDURE

Biospecimen Collection

Undergo collection of blood samples

OTHER

Electronic Health Record Review

Medical records are reviewed

OTHER

Questionnaire Administration

Ancillary studies

Trial Locations (1)

55905

Mayo Clinic in Rochester, Rochester

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
lead

Mayo Clinic

OTHER

NCT05740501 - Pharmacokinetic Profiling of Pembrolizumab and Nivolumab in Patients With Melanoma and/or Non-Small Cell Lung Cancer | Biotech Hunter | Biotech Hunter